Block 2: Inflammation and Eicosanoids Flashcards
Histamine: source, physiological response, mechanism
source: mast cells and basophils
response: vasodilation, increased vascular permeability, pain
mechanism: activation of GPCRs
Bradykinin: what is it, source, physiological response, mechanism
type: vasoactive peptide
source: endothelial cells
response: vasodilation, increased microvessel permeability, pain
mechanism: activation of GPCRs
Elevated CRP is associated with what?
increased risk of diabetes, hypertension, and cardiovascular disease
Cytokines: two pro-inflammatory examples, how they cause fever
IL-1, TNF-alpha
Increased expression of cyclooxygenase in hypothalamus -> increased formation of PGE2 which acts via cAMP to reset temperature set-point in hypothalamus -> increase body temp.
Prostaglandin: what is it, physiological response, mechanism
pro-inflammatory lipid mediator
response: vasodilation/vasoconstriction, pain, fever, platelet aggregation
mechanism: activation of specific GPCRs
Glucocorticoids: what they are, source, physiological response, mechanism
anti-inflammatory lipid mediators that inhibit arachidonic acid release
source: adrenal cortex
response: decrease expression of COX-2 and inhibits phospholipase-A2 (enzyme that cleaves phospholipid and releases arachidonic acid)
mechanism: activation of nuclear receptors
Leukotrienes: what is it, source, physiological response, mechanism
pro-inflammatory lipid mediator
response: increased vascular permeability, chemoattractant for neutrophils, bronchoconstriction
mechanism: activation of GPCRs
NSAIDs: mechanism
inhibition of cyclooxygenase, reduces production of inflammatory prostanoids
zafirlukast and zileuton: what each of them are, theapeutic use
zafirlukasat: competitve antagonist of leukotriene receptors
zileuton: inhibits 5-lipoxygenase and thus the synthesis of leukotrienes
use: prophylaxis and chronic treatment of asthma
TNF inhibitors (2)
etanercept, infliximab
etanercept and infliximab
TNF inhibitors
etanercept: receptor analog
infliximab: monoclonal antibody
precursor of eicosanoids
arachidonic acid
what enzyme synthesizes leukotrienes and from what precursor?
5-lipoxygenase from arachidonic acid
prophylaxis and chronic treatment of asthma (2)
zileuton and zafirlukast
Complement system: source, physiological response, mechanism
source: synthesized by liver, circulate in blood
physiological response: chemotaxis, release of mediators from neutrophils, increase vascular permeability
mechanism: complement complexes cause osmotic lysis, activation of GPCRs
Cytokines: physiological response, mechanism
physiological response:
TNF-alpha: fever, sepsis
IL-1: fever, fibroblast and lymphocyte proliferation
mechanism:
1. increase cyclooxygenase and lipoxygenase
2. increase adhesion molecule expression
3. induce collagenase (fibrosis)
function of phospholipase A2
hydrolyzes phospholipids to release arachidonic acid
function of cyclooxygenase
converts free arachidonic acid to PGH2 which is transformed enzymatically to prostacyclin, thromboxane, PGE2, PGF2
difference between COX-1 and COX-2
COX-1 is constitutive and expresed in all tissues
COX-2 is inducible and is more commonly seen in inflammation
function of 5-lipoxygenase
synthesize leukotrienes from arachidonic acid
types of drugs that inhibit phospholipase A2
glucocorticoids
type of drug that inhibit COX-1 and COX-2
NSAIDs
type of drug that decrease expression only of COX-2
glucocorticoids
inhibitors of lipoxygenase
zileuton and zafirlukast
physiological response of leukotrienes
bronchoconstriction, increase vascular permeability, chemotaxis
inhibits 5-lipoxygenase
zileuton
leukotriene receptor antagonist
zafirlukast
Eicosanoids related to pain in periphery
PGE2 and PGI2
what eicosanoid is important in fever?
PGE2
what second messager molecule is important in fever?
cAMP
what eicosanoid is responsible for platelet aggregation and what is the mechanism? include appropriate receptor
thromboxane
mechanism: activation of phospholipase A2 –> release of arachidonic acid –> converted to thromboxane by COX-1 –> stimulates TP receptors that couple to increase in calcium
does thromboxane cause vasocontstriction or vasodilation?
vasoconstriction
what eicosanoid is responsible for inhibiting platelet aggregation and what is the mechanism? include appropriate receptor
prostacyclin (PGI2)
mechanism: activation of phospholipase A2 –> release of arachidonic acid –> converted to prostacycling by COX-1 and COX-2 –> stimulates IP receptor that couples to cAMP
does prostacyclin cause vasoconstriction or vasodilation?
vasodilation
what is the cellular source of prostacyclin?
endothelial cells
what prostaglandins cause vasodilation of cardiovascular/vascular smooth muscle?
PGE2, PGI2
which prostaglandin is a potent vasoconstrictor?
thromboxane
circulating vasoconstrictor autocoid
angiotensin II
what prostaglandin maintains patency of ducrus arteriosus?
PGE2
what prostaglandins increase renal blood flow via vasodilation?
PGE2 and PGI2
which COX enzye is important in GI and how?
COX-1, synthesize cytoprotective prostaglandins that inhibit gastric acid secretion, stimulates release of mucus, increase gastric mucosal blood flow
why are therapeutic uses of prostaglandins limited?
adverse effects and short half-life
dinoprostone: analog of what, therapeutic uses, second messengers, adverse effects
PGE2 analog
uses: cervical ripening and termination of early pregnancy
second messengers: calcium, cAMP
adverse effects: GI-related, fever
what is the only PGE2 analog?
dinoprostone
misoprostone: analog of what, therapeutic use, second messenger, adverse effects
PGE1 analog
use: prevention of ulcers caused by NSAIDs
second messenger: cAMP
adverse effects: contraindicated in pregnancy
analogs of PGE1
misoprostol, alprostadil
alprostadil: analog of what, therapeutic uses, second messenger
PGE1 analog
uses: impotence, maintenance of patent ductus arteriosus
second messenger: cAMP
epoprostenol: analog of what, therapeutic use, mechanism (include appropriate receptor and second messenger)
PGI2 analog
use: primary pulmonary hypertension
mechanism: acts at PGI2 or IP receptor to cause a cAMP-mediated dilation of pulmonary artery vascular smooth muscle